FourWorld Capital Management’s Exagen XGN Stock Holding History

FourWorld Capital Management’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.77M	Buy	596,528 +156,578	+36%	+$590K	2.52%	14
2026 Q1	$1.32M	Buy	439,950 +166,950	+61%	+$646K	0.67%	19
2025 Q4	$1.66M	Buy	273,000 +46,000	+20%	+$419K	1.35%	13
2025 Q3	$2.49M	Buy	227,000 +18,473	+9%	+$164K	3.94%	8
2025 Q2	$1.46M	Buy	+208,527	New	+$1.27M	0.98%	13

Other funds holding XGN

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

FourWorld Capital Management's XGN Position: Q2 2026 in Review

FourWorld Capital Management increased its Exagen (XGN) stake by 36% in Q2 2026, buying an estimated $590K and bringing the position to 596,528 shares worth $2.77M. The position accounts for 2.52% of the portfolio, ranked #14.

FourWorld Capital Management first reported a position in XGN in Q2 2025 and has held it in 5 quarters since. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

FourWorld Capital Management held 596,528 shares of Exagen worth $2.77M as of Q2 2026.
FourWorld Capital Management bought 156,578 Exagen shares in Q2 2026, an estimated $590K.
Exagen made up 2.52% of FourWorld Capital Management's portfolio in Q2 2026, its #14 holding.
FourWorld Capital Management first reported a position in Exagen in Q2 2025 and has held it in 5 quarters since.
57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on FourWorld Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.